Reference : BM-520, an original TXA(2) modulator, inhibits the action of thromboxane A(2) and 8-i...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
BM-520, an original TXA(2) modulator, inhibits the action of thromboxane A(2) and 8-iso-prostaglandin F-2 alpha in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents
Rolin, Stéphanie* [> > > >]
Hanson, Julien* mailto [Université de Liège - ULiège > > Chimie pharmaceutique >]
Vastersaegher, Caroline [> > > >]
Cherdon, Céline [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie générale, bioch. et path. humaine et pathologiques >]
Pratico, Domenico [> > > >]
Masereel, Bernard [> > > >]
Dogné, Jean-Michel [Université de Liège - ULiège > Département de pharmacie > Département de pharmacie >]
* These authors have contributed equally to this work.
Prostaglandins & Other Lipid Mediators
Elsevier Science Inc
Yes (verified by ORBi)
New York
[en] thromboxane A2 ; antiplatelet agent ; isoprostanes
[en] Thromboxane A(2) (TXA(2)) and 8-iso-PGF(2 alpha). are two prostanoid agonists of the thromboxane A(2) receptor (TP), whose activation has been involved in platelet aggregation and atherosclerosis. Agents able to counteract the actions of these agonists are of great interest in the treatment and prevention of cardiovascular events. Here, we investigated in vitro and in vivo the pharmacological profile of BM-520, a new TP antagonist. In our experiments, this compound showed a great binding affinity for human washed platelets TP receptors, and prevented human platelet activation and aggregation induced by U-46619, arachidonic acid and 8-iso-PGF(2 alpha). The TP receptor antagonist property of BM-520 was confirmed by its relaxing effect on rat aorta smooth muscle preparations precontracted with U-46619 and 8-iso-PGF(2 alpha). Further, its TP antagonism was also demonstrated in vivo in guinea pig after a single intravenous injection (10 mg kg(-1)). We conclude that this novel TP antagonist could be a promising therapeutic tool in pathologies such as atherosclerosis where an increased production of TXA(2) and 8-iso-PGF2., as well as TP activation are well-established pathogenic events. (c) 2007 Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Dogne POLMcorrections finales.pdfPublisher postprint296.89 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.